A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders

Abstract Background Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The international journal of neuropsychopharmacology 2021-09, Vol.24 (9), p.734-748
Hauptverfasser: Romero-Miguel, Diego, Casquero-Veiga, Marta, MacDowell, Karina S, Torres-Sanchez, Sonia, Garcia-Partida, José Antonio, Lamanna-Rama, Nicolás, Romero-Miranda, Ana, Berrocoso, Esther, Leza, Juan C, Desco, Manuel, Soto-Montenegro, María Luisa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 748
container_issue 9
container_start_page 734
container_title The international journal of neuropsychopharmacology
container_volume 24
creator Romero-Miguel, Diego
Casquero-Veiga, Marta
MacDowell, Karina S
Torres-Sanchez, Sonia
Garcia-Partida, José Antonio
Lamanna-Rama, Nicolás
Romero-Miranda, Ana
Berrocoso, Esther
Leza, Juan C
Desco, Manuel
Soto-Montenegro, María Luisa
description Abstract Background Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model. Methods On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35–49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue. Results MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen). Conclusions MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2–ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains.
doi_str_mv 10.1093/ijnp/pyab036
format Article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8453277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ijnp/pyab036</oup_id><sourcerecordid>10.1093/ijnp/pyab036</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-11d0eb490e11177aeff759456e03fdc0bc8d148bba46612c4b3331c9569638863</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0Eon_gxhn5xmVD7bXjJBek7bZApS5Fopwjx550XTl2ZDsrls_ZD4TDlgounDyWf_PejB9Cbyh5T0nDzsy9G8_GvewIE8_QMeWiKUpK6fPfNS0oL6sjdBLjPSFLXjLxEh0xTkVZUnGMHlZ4vZVBqgTB_JTJeId9j9MW8GXfg0pxvm6M82qvrHGAbwPINIBL-GIKxt3hlfYWogKnAOfubylMKk1B2gXeQJKdt0YtsHQa3_wwOlvsYIYgRvw1Ow-QrSM2Dku8kbl20uKrYZjcjJlhsoepNl6DnYf5AlPI9Q6sH-c5Mn4eZO6_MNEHncVeoRe9tBFeP56n6PvHy9v15-L65tPVenVdqLx_KijVBDreEMjfVVUS-r4qG14KIKzXinSq1pTXXSe5EHSpeMcYo6opRSNYXQt2ij4cdMepG0DnL0h57XYMZpBh33pp2n9fnNm2d37X1jmHZVVlgcVBQAUfY4D-qZeSdk63ndNtH9PN-Nu__Z7gP3Fm4N0B8NP4f6lfbom2Jg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Romero-Miguel, Diego ; Casquero-Veiga, Marta ; MacDowell, Karina S ; Torres-Sanchez, Sonia ; Garcia-Partida, José Antonio ; Lamanna-Rama, Nicolás ; Romero-Miranda, Ana ; Berrocoso, Esther ; Leza, Juan C ; Desco, Manuel ; Soto-Montenegro, María Luisa</creator><creatorcontrib>Romero-Miguel, Diego ; Casquero-Veiga, Marta ; MacDowell, Karina S ; Torres-Sanchez, Sonia ; Garcia-Partida, José Antonio ; Lamanna-Rama, Nicolás ; Romero-Miranda, Ana ; Berrocoso, Esther ; Leza, Juan C ; Desco, Manuel ; Soto-Montenegro, María Luisa</creatorcontrib><description>Abstract Background Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model. Methods On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35–49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue. Results MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen). Conclusions MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2–ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains.</description><identifier>ISSN: 1461-1457</identifier><identifier>EISSN: 1469-5111</identifier><identifier>DOI: 10.1093/ijnp/pyab036</identifier><identifier>PMID: 34165516</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Animals ; Anti-Inflammatory Agents - administration &amp; dosage ; Anti-Inflammatory Agents - pharmacology ; Antioxidants - administration &amp; dosage ; Antioxidants - pharmacology ; Behavior, Animal - drug effects ; Brain Diseases, Metabolic - drug therapy ; Brain Diseases, Metabolic - etiology ; Disease Models, Animal ; Female ; Magnetic Resonance Imaging ; Male ; Minocycline - administration &amp; dosage ; Minocycline - pharmacology ; Nervous System Malformations - diagnostic imaging ; Nervous System Malformations - etiology ; Nervous System Malformations - pathology ; Neurodevelopmental Disorders - chemically induced ; Neurodevelopmental Disorders - drug therapy ; Neurodevelopmental Disorders - immunology ; Oxidative Stress - drug effects ; Positron-Emission Tomography ; Pregnancy ; Prenatal Exposure Delayed Effects - chemically induced ; Prenatal Exposure Delayed Effects - drug therapy ; Prenatal Exposure Delayed Effects - immunology ; Prepulse Inhibition - drug effects ; Rats ; Rats, Wistar ; Regular s ; Schizophrenia - chemically induced ; Schizophrenia - drug therapy ; Schizophrenia - immunology</subject><ispartof>The international journal of neuropsychopharmacology, 2021-09, Vol.24 (9), p.734-748</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of CINP. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of CINP.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-11d0eb490e11177aeff759456e03fdc0bc8d148bba46612c4b3331c9569638863</citedby><cites>FETCH-LOGICAL-c416t-11d0eb490e11177aeff759456e03fdc0bc8d148bba46612c4b3331c9569638863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453277/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453277/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1598,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34165516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romero-Miguel, Diego</creatorcontrib><creatorcontrib>Casquero-Veiga, Marta</creatorcontrib><creatorcontrib>MacDowell, Karina S</creatorcontrib><creatorcontrib>Torres-Sanchez, Sonia</creatorcontrib><creatorcontrib>Garcia-Partida, José Antonio</creatorcontrib><creatorcontrib>Lamanna-Rama, Nicolás</creatorcontrib><creatorcontrib>Romero-Miranda, Ana</creatorcontrib><creatorcontrib>Berrocoso, Esther</creatorcontrib><creatorcontrib>Leza, Juan C</creatorcontrib><creatorcontrib>Desco, Manuel</creatorcontrib><creatorcontrib>Soto-Montenegro, María Luisa</creatorcontrib><title>A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders</title><title>The international journal of neuropsychopharmacology</title><addtitle>Int J Neuropsychopharmacol</addtitle><description>Abstract Background Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model. Methods On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35–49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue. Results MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen). Conclusions MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2–ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents - administration &amp; dosage</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Antioxidants - administration &amp; dosage</subject><subject>Antioxidants - pharmacology</subject><subject>Behavior, Animal - drug effects</subject><subject>Brain Diseases, Metabolic - drug therapy</subject><subject>Brain Diseases, Metabolic - etiology</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Minocycline - administration &amp; dosage</subject><subject>Minocycline - pharmacology</subject><subject>Nervous System Malformations - diagnostic imaging</subject><subject>Nervous System Malformations - etiology</subject><subject>Nervous System Malformations - pathology</subject><subject>Neurodevelopmental Disorders - chemically induced</subject><subject>Neurodevelopmental Disorders - drug therapy</subject><subject>Neurodevelopmental Disorders - immunology</subject><subject>Oxidative Stress - drug effects</subject><subject>Positron-Emission Tomography</subject><subject>Pregnancy</subject><subject>Prenatal Exposure Delayed Effects - chemically induced</subject><subject>Prenatal Exposure Delayed Effects - drug therapy</subject><subject>Prenatal Exposure Delayed Effects - immunology</subject><subject>Prepulse Inhibition - drug effects</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Regular s</subject><subject>Schizophrenia - chemically induced</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - immunology</subject><issn>1461-1457</issn><issn>1469-5111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0Eon_gxhn5xmVD7bXjJBek7bZApS5Fopwjx550XTl2ZDsrls_ZD4TDlgounDyWf_PejB9Cbyh5T0nDzsy9G8_GvewIE8_QMeWiKUpK6fPfNS0oL6sjdBLjPSFLXjLxEh0xTkVZUnGMHlZ4vZVBqgTB_JTJeId9j9MW8GXfg0pxvm6M82qvrHGAbwPINIBL-GIKxt3hlfYWogKnAOfubylMKk1B2gXeQJKdt0YtsHQa3_wwOlvsYIYgRvw1Ow-QrSM2Dku8kbl20uKrYZjcjJlhsoepNl6DnYf5AlPI9Q6sH-c5Mn4eZO6_MNEHncVeoRe9tBFeP56n6PvHy9v15-L65tPVenVdqLx_KijVBDreEMjfVVUS-r4qG14KIKzXinSq1pTXXSe5EHSpeMcYo6opRSNYXQt2ij4cdMepG0DnL0h57XYMZpBh33pp2n9fnNm2d37X1jmHZVVlgcVBQAUfY4D-qZeSdk63ndNtH9PN-Nu__Z7gP3Fm4N0B8NP4f6lfbom2Jg</recordid><startdate>20210921</startdate><enddate>20210921</enddate><creator>Romero-Miguel, Diego</creator><creator>Casquero-Veiga, Marta</creator><creator>MacDowell, Karina S</creator><creator>Torres-Sanchez, Sonia</creator><creator>Garcia-Partida, José Antonio</creator><creator>Lamanna-Rama, Nicolás</creator><creator>Romero-Miranda, Ana</creator><creator>Berrocoso, Esther</creator><creator>Leza, Juan C</creator><creator>Desco, Manuel</creator><creator>Soto-Montenegro, María Luisa</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20210921</creationdate><title>A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders</title><author>Romero-Miguel, Diego ; Casquero-Veiga, Marta ; MacDowell, Karina S ; Torres-Sanchez, Sonia ; Garcia-Partida, José Antonio ; Lamanna-Rama, Nicolás ; Romero-Miranda, Ana ; Berrocoso, Esther ; Leza, Juan C ; Desco, Manuel ; Soto-Montenegro, María Luisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-11d0eb490e11177aeff759456e03fdc0bc8d148bba46612c4b3331c9569638863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents - administration &amp; dosage</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Antioxidants - administration &amp; dosage</topic><topic>Antioxidants - pharmacology</topic><topic>Behavior, Animal - drug effects</topic><topic>Brain Diseases, Metabolic - drug therapy</topic><topic>Brain Diseases, Metabolic - etiology</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Minocycline - administration &amp; dosage</topic><topic>Minocycline - pharmacology</topic><topic>Nervous System Malformations - diagnostic imaging</topic><topic>Nervous System Malformations - etiology</topic><topic>Nervous System Malformations - pathology</topic><topic>Neurodevelopmental Disorders - chemically induced</topic><topic>Neurodevelopmental Disorders - drug therapy</topic><topic>Neurodevelopmental Disorders - immunology</topic><topic>Oxidative Stress - drug effects</topic><topic>Positron-Emission Tomography</topic><topic>Pregnancy</topic><topic>Prenatal Exposure Delayed Effects - chemically induced</topic><topic>Prenatal Exposure Delayed Effects - drug therapy</topic><topic>Prenatal Exposure Delayed Effects - immunology</topic><topic>Prepulse Inhibition - drug effects</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Regular s</topic><topic>Schizophrenia - chemically induced</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romero-Miguel, Diego</creatorcontrib><creatorcontrib>Casquero-Veiga, Marta</creatorcontrib><creatorcontrib>MacDowell, Karina S</creatorcontrib><creatorcontrib>Torres-Sanchez, Sonia</creatorcontrib><creatorcontrib>Garcia-Partida, José Antonio</creatorcontrib><creatorcontrib>Lamanna-Rama, Nicolás</creatorcontrib><creatorcontrib>Romero-Miranda, Ana</creatorcontrib><creatorcontrib>Berrocoso, Esther</creatorcontrib><creatorcontrib>Leza, Juan C</creatorcontrib><creatorcontrib>Desco, Manuel</creatorcontrib><creatorcontrib>Soto-Montenegro, María Luisa</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The international journal of neuropsychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romero-Miguel, Diego</au><au>Casquero-Veiga, Marta</au><au>MacDowell, Karina S</au><au>Torres-Sanchez, Sonia</au><au>Garcia-Partida, José Antonio</au><au>Lamanna-Rama, Nicolás</au><au>Romero-Miranda, Ana</au><au>Berrocoso, Esther</au><au>Leza, Juan C</au><au>Desco, Manuel</au><au>Soto-Montenegro, María Luisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders</atitle><jtitle>The international journal of neuropsychopharmacology</jtitle><addtitle>Int J Neuropsychopharmacol</addtitle><date>2021-09-21</date><risdate>2021</risdate><volume>24</volume><issue>9</issue><spage>734</spage><epage>748</epage><pages>734-748</pages><issn>1461-1457</issn><eissn>1469-5111</eissn><abstract>Abstract Background Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model. Methods On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35–49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue. Results MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen). Conclusions MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2–ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>34165516</pmid><doi>10.1093/ijnp/pyab036</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1461-1457
ispartof The international journal of neuropsychopharmacology, 2021-09, Vol.24 (9), p.734-748
issn 1461-1457
1469-5111
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8453277
source MEDLINE; DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Animals
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - pharmacology
Antioxidants - administration & dosage
Antioxidants - pharmacology
Behavior, Animal - drug effects
Brain Diseases, Metabolic - drug therapy
Brain Diseases, Metabolic - etiology
Disease Models, Animal
Female
Magnetic Resonance Imaging
Male
Minocycline - administration & dosage
Minocycline - pharmacology
Nervous System Malformations - diagnostic imaging
Nervous System Malformations - etiology
Nervous System Malformations - pathology
Neurodevelopmental Disorders - chemically induced
Neurodevelopmental Disorders - drug therapy
Neurodevelopmental Disorders - immunology
Oxidative Stress - drug effects
Positron-Emission Tomography
Pregnancy
Prenatal Exposure Delayed Effects - chemically induced
Prenatal Exposure Delayed Effects - drug therapy
Prenatal Exposure Delayed Effects - immunology
Prepulse Inhibition - drug effects
Rats
Rats, Wistar
Regular s
Schizophrenia - chemically induced
Schizophrenia - drug therapy
Schizophrenia - immunology
title A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T08%3A56%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Characterization%20of%20the%20Effects%20of%20Minocycline%20Treatment%20During%20Adolescence%20on%20Structural,%20Metabolic,%20and%20Oxidative%20Stress%20Parameters%20in%20a%20Maternal%20Immune%20Stimulation%20Model%20of%20Neurodevelopmental%20Brain%20Disorders&rft.jtitle=The%20international%20journal%20of%20neuropsychopharmacology&rft.au=Romero-Miguel,%20Diego&rft.date=2021-09-21&rft.volume=24&rft.issue=9&rft.spage=734&rft.epage=748&rft.pages=734-748&rft.issn=1461-1457&rft.eissn=1469-5111&rft_id=info:doi/10.1093/ijnp/pyab036&rft_dat=%3Coup_pubme%3E10.1093/ijnp/pyab036%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34165516&rft_oup_id=10.1093/ijnp/pyab036&rfr_iscdi=true